Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. (PRPO) is a NASDAQ-traded healthcare biotechnology company focused on cancer diagnostics, and its news flow reflects both its operating activities and capital markets developments. The company’s stated mission is to address cancer misdiagnoses through diagnostic products and services that improve accuracy, laboratory workflow, and patient outcomes, and many of its announcements relate to progress toward that mission.
Investors following PRPO news can expect regular updates on the company’s pathology services division and products division. Precipio issues press releases when it files quarterly reports on Form 10-Q, summarizing revenue trends in its diagnostic services and product businesses, gross margin developments, and cash flow metrics. These releases often highlight performance in pathology services and product revenues, along with management commentary on operational efficiency and financial discipline.
Company news also covers product and technology milestones. Precipio has announced developments such as its BCR::ABL1 assay and a joint study with Memorial Sloan Kettering Cancer Center, describing study results, assay performance, and impacts on patient care and laboratory workflows. Additional product-related updates may discuss customer adoption, distributor activity, and the expansion of test panels and applications in customer laboratories.
Capital structure and corporate actions are another recurring theme in PRPO news. The company has issued releases about terminating its at-the-market Sales Agreement with A.G.P./Alliance Global Partners, entering into agreements with warrant holders for cash and cashless exercises, and repaying an advance from Change Healthcare. These updates provide context on share issuance, warrant activity, cash inflows, and the company’s efforts to maintain a clean balance sheet with limited debt.
Precipio also uses news releases to communicate about shareholder update calls, cybersecurity matters, and governance-related events. For example, it has announced quarterly shareholder calls, provided details on a limited-scope unauthorized access incident in its cloud file environment, and requested shareholder participation in voting to achieve quorum at its annual meeting. For investors and analysts, the PRPO news page offers a centralized view of these operational, financial, and corporate developments over time.
Precipio, Inc. (NASDAQ: PRPO) announced the appointment of Keith Meadors as Senior Vice President of its Products Division on June 13, 2022. Meadors brings over 30 years of executive experience in healthcare, most recently with Fresenius Kabi, where he expanded product offerings significantly. He has a history of driving revenue growth and product visibility. CEO Ilan Danieli expressed enthusiasm about Meadors’ expertise, highlighting its importance for the company’s potential. Precipio focuses on specialty cancer diagnostics with proprietary products.
Precipio, Inc. (PRPO) announced receiving CE-IVD approval for its HemeScreen® reagents in the EU, enabling sales across the UK and 27 EU countries. This certification validates that the HemeScreen panels meet essential European medical device requirements. The approved panels cover over 70% of hematologic malignancies, aiming to simplify workflows and deliver faster results for hematology/oncology labs. CEO Ilan Danieli emphasized this as a critical step towards expanding into new markets, enhancing revenue opportunities and addressing common laboratory challenges.
Precipio (NASDAQ: PRPO) has announced that the American Oncology Network (AON) has validated and will adopt its proprietary IV-Cell® culture media for use in clinical cytogenetics laboratories. This marks a significant step in Precipio's strategic business model as a specialty cancer diagnostics company, showcasing its ability to address unmet market needs with innovative products. AON's adoption of IV-Cell follows its previous launch of HemeScreen® testing with Precipio, highlighting cross-selling potential and operational efficiencies aimed at enhancing diagnostic accuracy.
Precipio, a specialty cancer diagnostics company, announced its participation in the Executive War College, taking place from April 26-28, 2022, in New Orleans. The company's innovative diagnostic platform, HemeScreen, was selected for presentation to laboratory executives. This endorsement showcases the technology's potential to improve clinical outcomes and laboratory efficiency. The presentation will occur on April 27 at 1:45 PM, with management available for discussions. CEO Ilan Danieli highlighted the importance of HemeScreen in enhancing diagnostic accuracy and patient care.
Precipio, Inc. (NASDAQ: PRPO) will host its Q4-2021 and year-end shareholder update call on April 4th, 2022, at 5:00 PM ET. This call aims to provide updates on the company’s core businesses. Interested participants can access the call by dialing 844-695-5519 or registering online for a direct dial-in number. Questions can be submitted in advance via email. A replay will be available on Precipio's investors page approximately 24 hours post-call. Precipio focuses on improving diagnostic accuracy in cancer treatment.
Precipio (NASDAQ: PRPO) announces the resignation of CFO Carl Iberger, effective March 21, 2022, citing family time as the reason. Matt Gage, the current Director of Financial Reporting and Analysis, has been appointed as the Interim CFO. Gage, with over 30 years of finance experience, including 25 years in publicly traded companies, is expected to ensure a smooth transition. The leadership change comes as Iberger reflects on a successful six-year tenure, emphasizing a positive outlook for Gage's contribution to the company's financial management.
Precipio (NASDAQ: PRPO) reported a 45% increase in revenues for 2021, totaling $8.9 million, driven primarily by pathology diagnostic testing. Q4 revenues reached $2.4 million, a 25% rise from the previous year. The HemeScreen product line is expected to contribute to further growth, with annualized contracts exceeding $1.6 million. Despite challenges from COVID-19, the company is optimistic about 2022, predicting significant revenue growth across its diagnostics segment, aiming to reduce cash burn and improve financial stability.
Precipio, Inc. (NASDAQ: PRPO) has announced that its HemeScreen RUO assay has received approval from the New York State Department of Health (NY DOH). This allows physician-owned laboratories (POLs) in New York to apply to run HemeScreen as a laboratory-developed test (LDT). The first customer, New York Cancer & Blood Specialists, estimates a potential for seven-figure revenues from HemeScreen, along with a Florida-based customer also utilizing the assay. This marks a significant milestone for Precipio, enhancing its market presence and potentially reducing cash burn.
Precipio, a specialty cancer diagnostics company (NASDAQ: PRPO), will host its Q3-2021 update conference call on November 15, 2021, at 5:00 PM ET. The call aims to provide updates on the company’s core businesses and can be accessed by calling 844-695-5519 or through pre-registration at their website. Precipio collaborates with renowned institutions like Yale and Dana-Farber to improve diagnostic accuracy in cancer care. Replay access will be available 24 hours post-call via their Investors page.
Precipio, Inc. (NASDAQ: PRPO) has signed a multi-year agreement with American Oncology Network (AON) to implement HemeScreen technology in AON's laboratory in Fort Myers, Florida. This partnership allows AON, the largest Physician Owned Laboratory, to reduce diagnostic turnaround times from 2-4 weeks to 1-4 days, significantly improving patient care. The deal is expected to generate seven-figure annual revenue for Precipio.
Both companies aim to enhance oncology diagnostics, with AON serving around 100,000 patients annually.
FAQ
What is the current stock price of Precipio (PRPO)?
What is the market cap of Precipio (PRPO)?
